BioSpace News Archive

Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 6, 2023.

Atara Biotherapeutics, Inc. today announced the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February 8, 2023.

As part of a shared commitment to bring better solutions for people suffering from depression, Clexio and Genetika+ are partnering to screen and characterize Clexio’s antidepressant pipeline using Genetika+'s iPSC-derived neurons platform.

Resolve Biosciences , the pioneer in Molecular Cartography™ technology, today announced the expansion of its end-to-end Meridian service offering for spatial transcriptomics data.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO).

Ashvattha Therapeutics today announced that the first patient has been enrolled in a Phase 1/2 clinical study to evaluate the safety, pharmacokinetics and biodistribution of an intravenously administered dose of [18F]OP-801 in healthy volunteers and in patients with amyotrophic lateral sclerosis (ALS) (NCT05395624).

Connect Biopharma Holdings Limited today announced it will be presenting, and hosting one-on-one meetings, at the following conferences in February and March 2023.

Arcturus Therapeutics Holdings Inc. today announced that the Company will participate in the following investor conferences.

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ProLectin-I injection.

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe.